New hope for tough-to-treat stroke? tirofiban tested in 516 patients
NCT ID NCT06037889
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether a powerful blood thinner called tirofiban can improve recovery in people with a specific type of stroke called branch atheromatous disease (BAD). BAD strokes often get worse quickly and have few good treatments. The trial enrolled 516 adults within 48 hours of stroke onset. Half received tirofiban plus standard care, and half received standard care alone. The main goal was to see if more people in the tirofiban group could return to near-normal function (no or minimal disability) after 90 days.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Tirofiban (a blood-thinning drug given through a vein)
- What this could lead to
- If it works, this could offer a more effective treatment for a type of stroke that often leads to rapid worsening and poor recovery.
- What could go wrong
- This is a completed Phase 3 trial, but results are not yet published. Tirofiban increases bleeding risk, which could outweigh benefits. The benefit may be small or not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BRANCH ATHEROMATOUS DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Affiliated Hospital of Chifeng University
Chifeng, Hebei, 024099, China
-
Beijing Shijitan Hospital, Capital Medical University
Beijing, Beijing Municipality, China
-
Beijing Shunyi Hospital
Beijing, Beijing Municipality, 101300, China
-
Botou City Hospital
Botou, Hebei, China
-
Cangzhou Central Hospital
Cangzhou, Hebei, China
-
Chengde Central Hospital
Chengde, Hebei, 067024, China
-
Deyang People's Hospital
Deyang, Sichuan, 618099, China
-
Hengshui People's Hospital
Hengshui, Hebei, 053099, China
-
Jinan Central Hospital
Jinan, Shandong, 250013, China
-
Meihekou Central Hospital
Meihekou, Jilin, 135022, China
-
Mianyang Central Hospital
Mianyang, Sichuan, 621099, China
-
North China University of Science and Technology Affiliated Hospital
Tangshan, Hebei, 063000, China
-
Peking Union Medical College Hospital
Beijing, Beijing Municipality, 100730, China
-
Shengli Oilfield Central Hospital
Dongying, Shandong, 257099, China
-
The First Affiliated Hospital of Xinxiang Medical Unversity
Xinxiang, Henan, 453100, China
-
The First Hospital of Tsinghua University
Beijing, Beijing Municipality, China
-
The First People's Hospital of Shangqiu
Shangqiu, Henan, 476005, China
-
The First People's Hospital of Yibin
Yibin, Sichuan, 644000, China
-
The Second Affiliated Hospital of Harbin Medical University
Harbin, Heilongjiang, 150001, China
-
The Second Hospital of Tianjin Medical University
Tianjing, Tianjing, 300211, China
-
The Second People's Hospital of Yibin
Yibin, Sichuan, 644000, China
-
The second hospital of Baoding
Baoding, Hebei, 071051, China
-
Tibet Autonomous Region People's Hospital
Lhasa, Tibet, 850000, China
-
Xuzhou Central Hospital
Xuzhou, Jiangsu, 221009, China
-
Yellow River SANMENXIA Hospital
Sanmenxia, Henan, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.